Technical Analysis for ONTX - Onconova Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 1.1 0.00% 0.00
ONTX closed down 3.51 percent on Tuesday, August 4, 2020, on 37 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ONTX trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -3.51%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Biopharmaceutical Cancer Chemical Compounds Organic Compounds Radiation Myelodysplastic Syndrome Pyridines Bemcentinib Lymphomas Protein Kinase Inhibitors Tyrosine Kinase Inhibitors Leukemias Head And Neck Cancers Kinase Metastatic Pancreatic Cancer Heterocyclic Compounds Piperazines

Is ONTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.84
52 Week Low 0.1027
Average Volume 17,301,857
200-Day Moving Average 0.47
50-Day Moving Average 0.70
20-Day Moving Average 0.95
10-Day Moving Average 1.17
Average True Range 0.14
ADX 49.79
+DI 35.51
-DI 12.72
Chandelier Exit (Long, 3 ATRs ) 1.14
Chandelier Exit (Short, 3 ATRs ) 0.97
Upper Bollinger Band 1.53
Lower Bollinger Band 0.37
Percent B (%b) 0.63
BandWidth 121.40
MACD Line 0.15
MACD Signal Line 0.16
MACD Histogram -0.0019
Fundamentals Value
Market Cap 10.83 Million
Num Shares 9.85 Million
EPS -2.57
Price-to-Earnings (P/E) Ratio -0.43
Price-to-Sales 9.36
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.19
Resistance 3 (R3) 1.19 1.17 1.18
Resistance 2 (R2) 1.17 1.14 1.17 1.17
Resistance 1 (R1) 1.13 1.13 1.12 1.13 1.16
Pivot Point 1.11 1.11 1.10 1.11 1.11
Support 1 (S1) 1.07 1.08 1.06 1.07 1.04
Support 2 (S2) 1.05 1.07 1.05 1.03
Support 3 (S3) 1.01 1.05 1.03
Support 4 (S4) 1.01